95 related articles for article (PubMed ID: 18171692)
1. Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells.
Spreafico A; Schenone S; Serchi T; Orlandini M; Angelucci A; Magrini D; Bernardini G; Collodel G; Di Stefano A; Tintori C; Bologna M; Manetti F; Botta M; Santucci A
FASEB J; 2008 May; 22(5):1560-71. PubMed ID: 18171692
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice.
Manetti F; Santucci A; Locatelli GA; Maga G; Spreafico A; Serchi T; Orlandini M; Bernardini G; Caradonna NP; Spallarossa A; Brullo C; Schenone S; Bruno O; Ranise A; Bondavalli F; Hoffmann O; Bologna M; Angelucci A; Botta M
J Med Chem; 2007 Nov; 50(23):5579-88. PubMed ID: 17929792
[TBL] [Abstract][Full Text] [Related]
3. New pyrazolo[3,4-d]pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization.
Indovina P; Giorgi F; Rizzo V; Khadang B; Schenone S; Di Marzo D; Forte IM; Tomei V; Mattioli E; D'Urso V; Grilli B; Botta M; Giordano A; Pentimalli F
Oncogene; 2012 Feb; 31(7):929-38. PubMed ID: 21785466
[TBL] [Abstract][Full Text] [Related]
4. Differentially activated Src kinase in chemo-naïve human primary osteosarcoma cells and effects of a Src kinase inhibitor.
Laschi M; Bernardini G; Geminiani M; Manetti F; Mori M; Spreafico A; Campanacci D; Capanna R; Schenone S; Botta M; Santucci A
Biofactors; 2017 Nov; 43(6):801-811. PubMed ID: 28786551
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
Hingorani P; Zhang W; Gorlick R; Kolb EA
Clin Cancer Res; 2009 May; 15(10):3416-22. PubMed ID: 19447875
[TBL] [Abstract][Full Text] [Related]
6. Proteomics and phosphoproteomics provide insights into the mechanism of action of a novel pyrazolo[3,4-d]pyrimidine Src inhibitor in human osteosarcoma.
Bernardini G; Laschi M; Serchi T; Spreafico A; Botta M; Schenone S; Arena S; Geminiani M; Scaloni A; Collodel G; Orlandini M; Niccolai N; Santucci A
Mol Biosyst; 2014 Jun; 10(6):1305-12. PubMed ID: 24615350
[TBL] [Abstract][Full Text] [Related]
7. New pyrazolo[3,4-d]pyrimidines endowed with A431 antiproliferative activity and inhibitory properties of Src phosphorylation.
Schenone S; Bruno O; Ranise A; Bondavalli F; Brullo C; Fossa P; Mosti L; Menozzi G; Carraro F; Naldini A; Bernini C; Manetti F; Botta M
Bioorg Med Chem Lett; 2004 May; 14(10):2511-7. PubMed ID: 15109642
[TBL] [Abstract][Full Text] [Related]
8. Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation.
Carraro F; Naldini A; Pucci A; Locatelli GA; Maga G; Schenone S; Bruno O; Ranise A; Bondavalli F; Brullo C; Fossa P; Menozzi G; Mosti L; Modugno M; Tintori C; Manetti F; Botta M
J Med Chem; 2006 Mar; 49(5):1549-61. PubMed ID: 16509573
[TBL] [Abstract][Full Text] [Related]
9. 2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors.
Dreassi E; Zizzari AT; Mori M; Filippi I; Belfiore A; Naldini A; Carraro F; Santucci A; Schenone S; Botta M
Eur J Med Chem; 2010 Dec; 45(12):5958-64. PubMed ID: 20970221
[TBL] [Abstract][Full Text] [Related]
10. An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.
He H; Hirokawa Y; Levitzki A; Maruta H
Cancer J; 2000; 6(4):243-8. PubMed ID: 11038144
[TBL] [Abstract][Full Text] [Related]
11. SRC family kinase inhibition through a new pyrazolo[3,4-d]pyrimidine derivative as a feasible approach for glioblastoma treatment.
Ceccherini E; Indovina P; Zamperini C; Dreassi E; Casini N; Cutaia O; Forte IM; Pentimalli F; Esposito L; Polito MS; Schenone S; Botta M; Giordano A
J Cell Biochem; 2015 May; 116(5):856-63. PubMed ID: 25521525
[TBL] [Abstract][Full Text] [Related]
12. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
Ischenko I; Guba M; Yezhelyev M; Papyan A; Schmid G; Green T; Fennell M; Jauch KW; Bruns CJ
Angiogenesis; 2007; 10(3):167-82. PubMed ID: 17486419
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
Ischenko I; Camaj P; Seeliger H; Kleespies A; Guba M; De Toni EN; Schwarz B; Graeb C; Eichhorn ME; Jauch KW; Bruns CJ
Oncogene; 2008 Dec; 27(57):7212-22. PubMed ID: 18794807
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative and pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells.
Navarra M; Celano M; Maiuolo J; Schenone S; Botta M; Angelucci A; Bramanti P; Russo D
BMC Cancer; 2010 Nov; 10():602. PubMed ID: 21050441
[TBL] [Abstract][Full Text] [Related]
15. Apoptotic effect of PP2 a Src tyrosine kinase inhibitor, in murine B cell leukemia.
Lee M; Kim JY; Koh WS
J Cell Biochem; 2004 Oct; 93(3):629-38. PubMed ID: 15378599
[TBL] [Abstract][Full Text] [Related]
16. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
17. Suppression of CD4+ T cell activation by a novel inhibitor of Src family kinases.
McRae BL; Wallace C; Dixon KF; Roux A; Mohan S; Jia Y; Presky DH; Tracey DE; Hirst GC
Int Immunopharmacol; 2005 Apr; 5(4):667-77. PubMed ID: 15710336
[TBL] [Abstract][Full Text] [Related]
18. Src family kinase inhibitors block amphiregulin-mediated autocrine ErbB signaling in normal human keratinocytes.
Kansra S; Stoll SW; Johnson JL; Elder JT
Mol Pharmacol; 2005 Apr; 67(4):1145-57. PubMed ID: 15615697
[TBL] [Abstract][Full Text] [Related]
19. SRC Family Kinase Inhibition in Ewing Sarcoma Cells Induces p38 MAP Kinase-Mediated Cytotoxicity and Reduces Cell Migration.
Indovina P; Casini N; Forte IM; Garofano T; Cesari D; Iannuzzi CA; Del Porro L; Pentimalli F; Napoliello L; Boffo S; Schenone S; Botta M; Giordano A
J Cell Physiol; 2017 Jan; 232(1):129-35. PubMed ID: 27037775
[TBL] [Abstract][Full Text] [Related]
20. Raf-1 kinase activation is uncoupled from downstream MEK/ERK pathway in cells treated with Src tyrosine kinase inhibitor PP2.
Lee M
Biochem Biophys Res Commun; 2006 Nov; 350(2):450-6. PubMed ID: 17010316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
